Holen Sie sich die Stockscreener-App
31.64
0.99%
-0.21
Schlusskurs vom Vortag:
$31.85
Offen:
$32.22
24-Stunden-Volumen:
151.88K
Relative Volume:
0.27
Marktkapitalisierung:
$1.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.97M
KGV:
-13.08
EPS:
-2.4189
Netto-Cashflow:
$-81.88M
1W Leistung:
+3.76%
1M Leistung:
-1.33%
6M Leistung:
-6.76%
1J Leistung:
+159.53%
1-Tages-Spanne:
$31.07
$32.60
1-Wochen-Bereich:
$30.35
$32.89
52-Wochen-Spanne:
$9.43
$45.85
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
31.64 | 1.52B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.68 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.20 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - Yahoo Finance
MBX Technical Analysis | Trend, Signals & Chart Patterns | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. thanks clinical trial participants as new therapies progress - Traders Union
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $91 - Moomoo
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - Sahm
Insider sale notice: 15,000 shares planned | MBX SEC FilingForm 144 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
MBX Biosciences (NASDAQ:MBX) Trading Down 8.8%Here's What Happened - MarketBeat
A Quick Look at Today's Ratings for MBX Biosciences(MBX.US), With a Forecast Between $56 to $86 - Moomoo
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements - Benzinga
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $86.00 at Citizens Jmp - MarketBeat
Q2 EPS Estimates for MBX Biosciences Boosted by Analyst - MarketBeat
Citizens raises MBX Biosciences stock price target on obesity drug data By Investing.com - Investing.com South Africa
Citizens raises MBX Biosciences stock price target on obesity drug data - Investing.com Nigeria
MBX Biosciences stock hits all-time high at 44.98 USD By Investing.com - Investing.com India
MBX Biosciences reports early obesity drug trial data By Investing.com - Investing.com Australia
Stifel raises MBX Biosciences stock price target to $56 on obesity data - Investing.com UK
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics PortfolioSlideshow (NASDAQ:MBX) 2026-05-11 - Seeking Alpha
Stifel raises MBX Biosciences stock price target to $56 on obesity data By Investing.com - Investing.com South Africa
MBX highlights early data for monthly obesity drug MBX-4291 - BioWorld News
Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing - marketscreener.com
MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan - Stock Titan
MBX (NASDAQ) affiliate sells multiple tranches of shares in Rule 144 notices - Stock Titan
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push - MarketBeat
MBX: MBX 4291 achieves 7% mean weight loss with strong tolerability in phase I, supporting monthly dosing - TradingView
Insiders Of MBX Biosciences Are Up 125% On Their US$1.06m Purchase - Moomoo
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $70.00 - MarketBeat
MBX Biosciences Reports Positive Phase 1 Results for Once-Monthly Obesity Drug MBX 4291 and Expands Obesity Pipeline - Minichart
MBX: MBX's obesity pipeline advances with promising once-monthly candidates and strong financial runway - TradingView
MBX Biosciences : May 2026 Obesity Day Presentation – Final - marketscreener.com
MBX Biosciences stock hits all-time high at 44.98 USD - Investing.com
Obesity portfolio update features new clinical data from MBX Biosciences, Inc. - Traders Union
MBX Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating - marketscreener.com
MBX Biosciences Highlights Positive Phase 1 Obesity Data - TipRanks
MBX Biosciences reports early obesity drug trial data - Investing.com
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - The Manila Times
MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing - marketscreener.com
Brokers Set Expectations for MBX Biosciences Q1 Earnings - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Momentum - Sahm
Wall Street Zen Upgrades MBX Biosciences (NASDAQ:MBX) to Hold - MarketBeat
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):